Bracco clinical trials

The registry lists 66 studies whose lead sponsor is Bracco or one of 4 companies grouped under it. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 66. Browse all 66 →

• Lumason® Infusion vs. Bolus AdministrationsRecruitingNCT06400004Phase 3

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical RecurrenceRecruitingNCT07569926Phase 4

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted after Blue Earth Diagnostics became part of Bracco

• [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsRecruitingNCT07702292Phase 2

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted after Blue Earth Diagnostics became part of Bracco

• [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsRecruitingNCT07432633Phase 1/2

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted after Blue Earth Diagnostics became part of Bracco

• Anti-tumour Activity of (177Lu) rhPSMA-10.1 InjectionRecruitingNCT05413850Phase 1/2

  Sponsor listed in the registry: Blue Earth Therapeutics Ltd

• Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical ProstatectomyCompletedNCT06604442Phase 4

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted after Blue Earth Diagnostics became part of Bracco

• Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate CancerCompletedNCT03995888Phase 1

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted before Blue Earth Diagnostics became part of Bracco

• A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate CancerTerminatedNCT06516510Early Phase 1

  Sponsor listed in the registry: Blue Earth Therapeutics Ltd

• Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer RecurrenceCompletedNCT04186845Phase 3

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted after Blue Earth Diagnostics became part of Bracco

• Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain MetastasesCompletedNCT04410133Phase 3

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted after Blue Earth Diagnostics became part of Bracco

• Thyroid Function of Pediatric Subjects Following Isovue® AdministrationTerminatedNCT03779906Phase 4

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)CompletedNCT04410367Phase 2

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted after Blue Earth Diagnostics became part of Bracco

• Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.CompletedNCT04186819Phase 3

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted after Blue Earth Diagnostics became part of Bracco

• BR55 in Characterization of Ovarian LesionsTerminatedNCT03493464Phase 2

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Transabdominal Ultrasound With BR55 for Characterization of Pancreatic LesionsTerminatedNCT03486327Phase 2

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Optimal Timing of BR55 CEUS of the OvariesTerminatedNCT04248153Phase 2

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• BR55 in Prostate Cancer: an Exploratory Clinical TrialCompletedNCT01253213Early Phase 1

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Renal MRA Crossover Study Comparing Multihance to Another Contrast AgentCompletedNCT00415805Phase 3

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Study With Oral Isovue in Abdominopelvic CTCompletedNCT04453059

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® CatheterWithdrawnNCT05079906Not applicable

  Sponsor listed in the registry: Acist Medical Systems · Acist Medical Systems — acquired company within the Bracco group

• Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142CompletedNCT02552238Phase 3

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141CompletedNCT02522481Phase 3

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate CancerCompletedNCT02142608Phase 1/2

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Multihance at 3 Tesla (3T) in Brain TumorsCompletedNCT00395863Phase 4

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Kidney Damage in Patients With Moderate Fall in eGFRCompletedNCT01136876Phase 4

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With ControlCompletedNCT03108378

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Evaluation of Safety and Efficacy of Lumason in Pediatric EchocardiographyTerminatedNCT02282163Phase 3

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrsCompletedNCT03750188

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Post-Market Registry of the ACIST CPM System and Navvus Catheter in Clinical PracticeCompletedNCT02060682

  Sponsor listed in the registry: Acist Medical Systems · Acist Medical Systems — acquired company within the Bracco group

• Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcerCompletedNCT02578940Phase 3

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted before Blue Earth Diagnostics became part of Bracco

• 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer TreatmentCompletedNCT02680041Phase 3

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted before Blue Earth Diagnostics became part of Bracco

• Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)CompletedNCT02443571

  Sponsor listed in the registry: Blue Earth Diagnostics · First submitted before Blue Earth Diagnostics became part of Bracco

• SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion CharacterizationCompletedNCT00829413Phase 3

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS PatientsCompletedNCT03147989

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion CharacterizationCompletedNCT00788697Phase 3

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• A Multicenter Study of Iomeron®-400 Used With Multi-detector Computed Tomography Angiography (MDCTA)CompletedNCT02596048Phase 4

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Crossover Comparison of MultiHance and DotaremCompletedNCT02070380Phase 4

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Safety of SonoVue on Pulmonary HemodynamicsCompletedNCT01306292Phase 2

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve MeasurementStatus unknownNCT02577484

  Sponsor listed in the registry: Acist Medical Systems · Acist Medical Systems — acquired company within the Bracco group

• Retrospective Study of MRI in Pediatric PatientsCompletedNCT02291822

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the BrainCompletedNCT01613417Phase 4

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney DiseaseCompletedNCT00600834

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney DiseaseCompletedNCT00600951

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Kidney Damage In Patients With Severe Fall In eGFRTerminatedNCT01136915Phase 4

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Kidney Damage in Patients With Normal eGFRCompletedNCT01137786Phase 4

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Multidetector Computed Tomography (MDCT) Tailored ProtocolCompletedNCT01737333

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Isovue in Peripheral Digital Subtraction Angiography (DSA)CompletedNCT01075217Phase 4

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Coronary MDCTA With Iopamidol Injection 370CompletedNCT00558792Phase 2

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)CompletedNCT00773409

  Sponsor listed in the registry: Bracco Diagnostics, Inc

• Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI ScanningCompletedNCT01424774

  Sponsor listed in the registry: Bracco Diagnostics, Inc